EGFR and lymphangioma: In recent years, the growing incidence of LM is likely due to improved supportive care as well as prolonged survival in patients with targetable mutations, particularly epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations [2, 3].